ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1942 • ACR Convergence 2021

    Occurrence of Basal Cell and Squamous Cell Carcinomas of the Skin Under Different DMARD Therapies

    Imke Redeker1, Peter Herzer2, Cornelia Kühne3, Ilka Schwarze4, Martin Schaefer5 and Anja Strangfeld6, 1German Rheumatism Research Centre (DRFZ), Berlin, Germany, 2Scientific Advisory Board, Munich, Germany, 3Rheumatologist, Haldensleben, Germany, 4Rheumatologist, Leipzig, Germany, 5German Rheumatism Research Center, Berlin, Germany, 6Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany

    Background/Purpose: Squamous and basal cell carcinomas are the most common malignancies of the skin; they are subsumed under non-melanoma skin cancer (NMSC). The risk of…
  • Abstract Number: 1940 • ACR Convergence 2021

    Malignancies in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

    Jeffrey Curtis1, Kunihiro Yamaoka2, Yi-Hsing Chen3, Levent M Gunay4, Naonobu Sugiyama5, Carol A Connell6, Cunshan Wang6, Joseph Wu6, Sujatha Menon6, Ivana Vranic7 and Juan J Gomez-Reino8, 1Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 2School of Medicine, Department of Rheumatology and Infectious Diseases, Kitasato University, Sagamihara, Japan, 3Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 4Pfizer Inc, Istanbul, Turkey, 5Pfizer Japan Inc, Tokyo, Japan, 6Pfizer Inc, Groton, CT, 7Pfizer Inc, Tadworth, Surrey, United Kingdom, 8Hospital Clínico Universitario, Santiago de Compostela, Spain

    Background/Purpose: ORAL Surveillance (NCT02092467) was a post-authorization safety study to assess the relative risk of tofacitinib vs TNF inhibitors (TNFi), based on observed increases in…
  • Abstract Number: 1939 • ACR Convergence 2021

    Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study

    Farzin Khosrow-Khavar, Seoyoung Kim, Hemin Lee, Su Been Lee and Rishi Desai, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Recent reports from a post-marketing safety trial, “ORAL Surveillance”, indicated an increased risk of cardiovascular (CV) outcomes in RA patients treated with tofacitinib. Thus,…
  • Abstract Number: 1935 • ACR Convergence 2021

    Skewed Escape from X-inactivation: Insights into the Female Bias of Sjögren’s Syndrome

    Teressa Shaw1, Wei Zhang2, Sara McCoy3, Xueer Qiu1, Adam Pagenkopf1, Robert Hal Scofield4, Jacques Galipeau3 and Yun Liang1, 1University of Wisconsin-Madison, Madison, WI, 2University of California San Diego, La Jolla, CA, 3University of Wisconsin, Madison, WI, 4Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Many autoimmune diseases feature increased prevalence in females, with primary Sjögren's syndrome (pSS) being the most female-predominant autoimmune disease with a female-to-male ratio of…
  • Abstract Number: PP04 • ACR Convergence 2021

    Dual Roles: Thriving with SLE as a Medical Student

    Chieh Lo1 and Song-Chou Hsieh2, 1School of Medicine, I-Shou Univerity, Kaohsiung, Taiwan (Republic of China), 2Division of Immunology, Allergy and Rheumatology, Department of Medicine, National Taiwan University Hospital, Taipei, Taiwan (Republic of China)

    Background/Purpose: A few days after my 18th birthday, I walked into a rheumatology clinic for the first time. I had ulcers in my mouth, felt…
  • Abstract Number: PP05 • ACR Convergence 2021

    Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information

    Michael Linn1, Spenser Mestel2 and Susie Ratledge3, 1Relapsing Polychondritis Foundation, New York, NY, 2New York, NY, 3Relapsing Polychondritis: Secular Science and Support group, Chattanooga, TN

    Background/Purpose: Before I became ill in 2017, I was a registered nurse with a degree in health science who'd often educate patients about how they…
  • Abstract Number: PP08 • ACR Convergence 2021

    Should I Get the COVID-19 Vaccine With My RA? Using Evidence-Based Resources for Decision-Making

    Aberdeen Allen, Colgate Palmolive, Parlin, NJ

    Background/Purpose: Patients with autoimmune rheumatic diseases have concerns about getting the COVID-19 vaccine. As vaccines began to receive emergency use authorization, individuals with conditions like…
  • Abstract Number: PP07 • ACR Convergence 2021

    How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic

    Wigna Cruz, Puerto Rico

    Background/Purpose: I was experiencing joint pain especially in my wrists, which led me to see my physician for testing. Initially I was misdiagnosed with lupus.…
  • Abstract Number: PP09 • ACR Convergence 2021

    Family Planning while Living with Rheumatoid Arthritis

    Shannan O'Hara-Levi, Monroe, NY

    Background/Purpose: Over the course of my 30+ years living with Polyarticular Juvenile Rheumatoid Arthritis, I have never had long term success on any one biologic treatment,…
  • Abstract Number: PP06 • ACR Convergence 2021

    Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) /  My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.

    Michael Linn1 and Dan Smith2, 1Relapsing Polychondritis Foundation, New York, NY, 2Relapsing Polychondritis Foundation, Canton, MI

    Background/Purpose: In March 2020, I was diagnosed as having relapsing polychondritis ("RP"), an understudied, underdiagnosed, and undertreated debilitating autoimmune disease that can be fatal if…
  • Abstract Number: 1933 • ACR Convergence 2021

    Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus (SLE) in United States Patients: Data from the COVID-19 Global Rheumatology Alliance

    Manuel Ugarte-Gil1, Graciela Alarcn2, Andrea Seet3, Zara Izadi3, Ali Duarte-Garcia4, Emily Gilbert5, Maria Valenzuela-Almada6, Leanna Wise7, Jeffrey Sparks8, Tiffany Hsu9, Kristin D'Silva10, Naomi Patel10, Emily Sirotich11, Jean Liew12, Jonathan Hausmann13, Paul Sufka14, Rebecca Grainger15, Suleman Bhana16, Wendy Costello17, Zachary Wallace18, Lindsay Jacobsohn19, Anja Strangfeld20, Elsa Frazão Mateus21, Kimme Hyrich22, Laure Gossec23, Loreto Carmona24, Saskia Lawson-Tovey22, Lianne Kearsley-Fleet25, Martin Schaefer26, Pedro Machado27, Philip Robinson28, Milena Gianfrancesco3 and Jinoos Yazdany3, 1Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, 2University of Alabama at Birmingham, Birmingham, AL, 3University of California San Francisco, San Francisco, CA, 4Mayo Clinic, Rochester, MN, 5Mayo Clinic, Jacksonville, FL, 6Division of Rheumatology, Mayo Clinic, Rochester, MN, 7LAC+USC/Keck Medicine of USC, Pasadena, CA, 8Brigham and Women's Hospital, Boston, MA, 9Brigham and Women's Hospital, Jamaica Plain, MA, 10Massachusetts General Hospital, Boston, MA, 11McMaster University, Hamilton, ON, Canada, 12Boston University, Boston, MA, 13Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 14HealthPartners, Eagan, MN, 15University of Otago, Wellington, New Zealand, 16Crystal Run Health, Montvale, NJ, 17Irish Children's Arthritis Network, Bansha, Ireland, 18Massachusetts General Hospital, Newton, MA, 19University of California San Francisco, Antioch, CA, 20Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 21Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, 22University of Manchester, Manchester, United Kingdom, 23Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, 24Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, 25Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 26German Rheumatism Research Center, Berlin, Germany, 27Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 28Faculty of Medicine, The University of Queensland, Herston, Australia

    Background/Purpose: Hispanic and African American race/ethnicities have been associated with poor COVID-19 outcomes in the general population and in rheumatic disease patients within the COVID-19…
  • Abstract Number: PP13 • ACR Convergence 2021

    CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease

    Chantelle Marcial, Boston, MA

    Background/Purpose: At 19, I was mis-diagnosed with Lupus as it was a common condition in my family. My treatment at that time was mainly DMARDs,…
  • Abstract Number: PP11 • ACR Convergence 2021

    “Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases

    Trishtha Peters1 and Natasha Trehan2, 1University of Ontario, Toronto, ON, Canada, 2University of Ottawa, Toronto, ON, Canada

    Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…
  • Abstract Number: 1936 • ACR Convergence 2021

    A Neutrophil Degranulation Signature Identifies Proliferative Lupus Nephritis

    Andrea Fava1, Jessica Li1, Daniel Goldman2, Brendan Antiochos1, Jose Monroy-Trujillo1, Derek Fine1, Mohamed G. Atta1, Jill Buyon3, Joel Guthridge4, Judith James4, Michelle Petri2 and Accelerating Medicines Partership (AMP) RA/SLE Network5, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3NYU School of Medicine, New York, NY, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Brigham and Women's Hospital, Everett, MA

    Background/Purpose: The identification of intrarenal pathological processes is key to develop better diagnostic and treatment strategies in lupus nephritis (LN). But the direct comprehensive study…
  • Abstract Number: 1931 • ACR Convergence 2021

    The Burden of Thirty-day Readmission and Independent Predictors of Readmission in Patients with Systemic Lupus Erythematosus: A Nationwide Analysis

    Ashu Acharya1, Saffa Iftikhar1, Yasmin Khader1, Sachit Sharma1, Joan N Gekonde1, Rawish Fatima1, Cameron J Burmeister1 and Nezam Altorok2, 1University of Toledo Medical Center, Toledo, OH, 2University of Toledo, Toledo, OH

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic immune-mediated disease with 20-25% patients needing hospital admission annually. Early readmissions add to the clinical and economic…
  • « Previous Page
  • 1
  • …
  • 643
  • 644
  • 645
  • 646
  • 647
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology